Choice of starting dose and escalation for phase I studies of antitumor agents.
about
Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trialsPatients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations.Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience.Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in JapanEvaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience.Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.Pharmacodynamic analysis of hematologic profiles.
P2860
Q33849805-2B4D4093-C69C-4DC4-A55E-F6DD26D3CD04Q36422375-6A24DCA8-5891-419B-827A-328FB01BBECAQ36640945-DCC8FD08-1CC5-4305-B754-E53A1C5054AEQ37383697-D0C8FCF0-3BBF-42CD-B959-01C55725FD07Q38907890-DBA6A7E1-F887-4637-A235-249678F5BE10Q43846394-67B713C8-0AE6-4A22-8C7E-5859CE032946Q51640753-44334CA3-02F2-4580-9FC0-1E986C68B980Q52365340-F86BC36A-E447-4AF7-AAEE-4A9976B9FE99
P2860
Choice of starting dose and escalation for phase I studies of antitumor agents.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Choice of starting dose and escalation for phase I studies of antitumor agents.
@ast
Choice of starting dose and escalation for phase I studies of antitumor agents.
@en
type
label
Choice of starting dose and escalation for phase I studies of antitumor agents.
@ast
Choice of starting dose and escalation for phase I studies of antitumor agents.
@en
prefLabel
Choice of starting dose and escalation for phase I studies of antitumor agents.
@ast
Choice of starting dose and escalation for phase I studies of antitumor agents.
@en
P2093
P356
P1476
Choice of starting dose and escalation for phase I studies of antitumor agents.
@en
P2093
P2888
P304
P356
10.1007/BF00685555
P577
1992-01-01T00:00:00Z